首页|Glucose-responsive artificial promoter-mediated insulin gene transfer improves glucose control in diabetic mice

Glucose-responsive artificial promoter-mediated insulin gene transfer improves glucose control in diabetic mice

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
AIM:To investigate the effect of insulin gene therapy using a glucose-responsive synthetic promoter in type 2 diabetic obese mice.METHODS:We employed a recently developed novel insulin gene therapy strategy using a synthetic promoter that regulates insulin gene expression in the liver in response to blood glucose level changes.We intravenously administered a recombinant adenovirus expressing furin-cleavable rat insulin under the control of the synthetic promoter (rAd-SP-rINSfur) into diabetic Leprdb/db mice.A recombinant adenovirus expressing β-galactosidase under the cytomegalovirus promoter was used as a control (rAd-CMV-βgal).Blood glucose levels and body weights were monitored for 50 d.Glucose and insulin tolerance tests were performed.Immunohistochemical staining was performed to investigate islet morphology and insulin content.RESULTS:Administration of rAd-SP-rINSfur lowered blood glucose levels and normoglycemia was maintained for 50 d,whereas the rAd-CMV-βgal control virus-injected mice remained hyperglycemic.Glucose tolerance tests showed that rAd-SP-rINSfur-treated mice cleared exogenous glucose from the blood more efficiently than control virus-injected mice at 4 wk [area under the curve (AUC):21 508.80 ± 2248.18 vs 62 640.00 ± 5014.28,P ＜ 0.01] and at 6 wk (AUC:29 956.60 ± 1757.33 vs 60 016.60 ± 3794.47,P ＜ 0.01).In addition,insulin sensitivity was also significantly improved in mice treated with rAd-SP-rINSfur compared with rAd-CMV-βgal-treated mice (AUC:9150.17±1007.78 vs 11 994.20 ± 474.40,P ＜ 0.05).The islets from rAd-SP-rINSfur-injected mice appeared to be smaller and to contain a higher concentration of insulin than those from rAd-CMV-βgal-injected mice.CONCLUSION:Based on these results,we suggest that insulin gene therapy might be one therapeutic option for remission of type 2 diabetes.

Insulin gene therapySynthetic promoterGlucose-responsive elementLiver-specific promoterType 2 diabetes

Jaeseok Han、Eung-Hwi Kim、Woohyuk Choi、Hee-Sook Jun

展开 >

Department of Microbiology and Infectious Diseases, University of Calgary, 3330 Hospital Drive N.W.Calgary,Alberta T2N 4N1, Canada

Del E.Webb Neuroscience, Aging and Stem Cell Research Center, Sanford Burnham Medical Research Institute,La Jolla, CA 92037, United States

Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 7-45 Sondo-dong , Yeonsu-ku, Incheon 406-840, South Korea

College of Pharmacy, Gachon University, 7-45 Sondo-dong, Yeonsu-ku, Incheon 406-840, South Korea

展开 >

A grant from Innovative Research Institute for Cell Therapy Project,South Korea

A062260

2012

10.3748/wjg.v18.i44.6420

世界胃肠病学杂志(英文版)
太原消化病研治中心

世界胃肠病学杂志(英文版)

SCI
影响因子：1.001
ISSN：1007-9327
年,卷(期)：2012.18(44)
  • 1
  • 37